Over a one-year follow-up period, the QoL remained stable, while the societal costs decreased in both G+/P- individuals and HCM patients, and a significant reduction in BoD was observed among symptomatic oHCM patients, in particular those classified as NYHA III.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. However, prospective data on the burden of disease (BoD) remain limited. Baseline results from the AFFECT-HCM cohort reported reduced quality of life (QoL) and increased societal costs among younger (working-aged), symptomatic HCM patients, primarily driven by productivity losses.
This study assesses changes in BoD, defined as QoL combined with healthcare-related costs of HCM patients and genotype-positive/phenotype-negative (G+/P-) individuals after one year.
AFFECT-HCM is a multicenter, prospective cohort study conducted in the Netherlands. Participants were stratified based on phenotype (G+/P- subjects, obstructive (oHCM) and non-obstructive HCM (nHCM) patients), and symptomatic status based on the New York Heart Association (NYHA) class (symptomatic= NYHA≥II). After one year, clinical events (including mortality, septal reduction therapy and ICD-implantation), change in NYHA class and medication use were reported. Disease-specific QoL was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) and costs were evaluated using the Medical Consumption Questionnaire (iMCQ) and the Productivity Costs Questionnaire (iPCQ). Bootstrapping was performed for the cost data due to the level of skewness observed.
479 of the 506 (95%) participants completed the one-year follow-up: 79 G+/P- subjects, 298 nHCM patients and 102 oHCM patients; 38% female and median age 58 years (45-67). Six HCM patients died, including 1 sudden cardiac death among nHCM patients. 18 patients underwent septal reduction therapy, 21 patients (17 nHCM; 4 oHCM) received an ICD. Significant improvement in NYHA class was observed among oHCM patients (P=0.010). Sodium-glucose cotransporter-2 inhibitors (p<0.001 in nHCM) and mavacamten (p=0.0014 in oHCM were initiated more. Completion rate for QoL and cost questionnaires were 86%. KCCQ scores remained stable in G+/P- individuals, nHCM and oHCM patients. However median KCCQ scores significantly improved among symptomatic HCM patients (68 to 76 points, P=0.003), including 53% oHCM and 34% nHCM patients. Societal costs were significantly lower at follow-up compared to baseline in all phenotypes (Table 1a). However, societal costs in NYHA II HCM patients significantly increased (P<0.001), primarily driven by healthcare costs and productivity losses (Table 1b).
Over a one-year follow-up period, the QoL remained stable, while the societal costs decreased in both G+/P- individuals and HCM patients. A significant reduction in BoD was observed among symptomatic oHCM patients, in particular those classified as NYHA III. This improvement may be related to the effective treatment of oHCM patients with septal reduction therapy and the introduction of mavacamten during the follow-up period.Figure 1.change KCCQ in nHCM/oHCM by NYHATable 1.Costs phenotypes, NYHA class
Obstructive hypertrophic cardiomyopathy (oHCM) is associated with excess mortality and frequent cardiovascular (CV) events. Real-world evidence is limited and existing published estimates may differ according to cohort definition, severity mix, and follow-up duration.
The objective of the study was to desc...
A. Vimont, J. Carette, P. Gebrehiwet et al.· European Heart Journal· 0 citations
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, affecting 1 in 500 individuals globally. HCM varies from asymptomatic disease to a highly symptomatic obstructive HCM (oHCM).
This study characterized the Swedish HCM population and assessed healthcare utilization with...
O. Braun, A. Damlin, C. Christersson et al.· European Heart Journal· 0 citations
The findings indicate that standard treatment thresholds may be insufficient, and more intensive risk-factor management is warranted in HCMG- patients, and that standard treatment thresholds may be insufficient.
P. M. Marin, K. Halim, P. Poveda et al.· European Heart Journal· 0 citations
BACKGROUND
The impact of coexisting type 2 diabetes mellitus (T2DM) on the phenotype and prognosis of hypertrophic cardiomyopathy (HCM) remains insufficiently studied. We aimed to evaluate the structural, functional, and prognostic effects of T2DM in HCM using cardiac magnetic resonance (CMR).
METHODS
This retrospect...
Yu-Kun Cao, Yu-Min Li, Zhenglin Ming et al.· International Journal of Car...· 0 citations
Background:
Symptoms and functional impairments have historically represented the primary targets of hypertrophic cardiomyopathy (HCM) management. Obesity has been shown to be associated with worse symptoms and clinical outcomes in HCM, but the extent to which obesity influences patient-reported health status across...
J. Ostrominski, B. Claggett, A. Axelsson Raja et al.· Circulation· 0 citations
The contemporary incidence and prevalence of HCM in the community is much lower than previously reported rates, as is the rate of HCM related SCD regardless of gender, and existing SCD prediction tools are ineffective in the real world setting.
N. Farooqui, Amr Moustafa, Bernard Gersch et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.